Hypoxia-inducible transcription factor (HIF)-1α stabilization by actin-sequestering protein, thymosin beta-4 (TB4) in Hela cervical tumor cells

Cancer Letters

Volumn 264, Issue 1, 2008, Pages 29-35

  Oh, Jin Mi ^a   Ryoo, In Ja ^b   Yang, Young ^c   Kim, Hyun Sun ^a   Yang, Kyu Hwan ^d   Moon, Eun Yi ^a  

^a Sejong University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Sookmyung Women's University   (South Korea)

^d Gachon University College of Medicine   (South Korea)

Author keywords

ERK; Hela cell; HIF 1 ; Hypoxia; Thymosin beta 4

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; THYMOSIN BETA4; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CELL DEATH; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; DNA RESPONSIVE ELEMENT; HELA CELL; HUMAN; HUMAN CELL; HYPOXIA RESPONSE ELEMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; TRANSACTIVATION; WESTERN BLOTTING;

ACTINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL HYPOXIA; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PACLITAXEL; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYMOSIN; UTERINE CERVICAL NEOPLASMS;

EID: 42649086024     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.004     Document Type: Article

References (36)

1. Huff T., Muller C.S., Otto A.M., Netzker R., and Hannappel E. Beta-thymosins, small acidic peptides with multiple functions. Int. J. Biochem. Cell Biol. 33 (2001) 205-220
2. Domanski M., Hertzog M., Coutant J., Gutsche-Perelroizen I., Bontems F., Carlier M.F., Guittet E., and van Heijenoort C. Coupling of folding and binding of thymosin beta4 upon interaction with monomeric actin monitored by nuclear magnetic resonance. J. Biol. Chem. 279 (2004) 23637-23645
3. Hertzog M., van Heijenoort C., Didry D., Gaudier M., Coutant J., Gigant B., Didelot G., Preat T., Knossow M., Guittet E., and Carlier M.F. The beta-thymosin/WH2 domain; structural basis for the switch from inhibition to promotion of actin assembly. Cell 117 (2004) 611-623
4. Huff T., Otto A.M., Muller C.S., Meier M., and Hannappel E. Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen. FASEB J. 16 (2002) 691-696
5. Malinda K.M., Sidhu G.S., Mani H., Banaudha K., Maheshwari R.K., Goldstein A.L., and Kleinman H.K. Thymosin beta4 accelerates wound healing. J. Invest. Dermatol. 113 (1999) 364-368
6. Cha H.J., Jeong M.J., and Kleinman H.K. Role of thymosin beta4 in tumor metastasis and angiogenesis. J. Natl. Cancer Inst. 95 (2003) 1674-1680
7. Goldstein A.L. Thymosin beta4: a new molecular target for antitumor strategies. J. Natl. Cancer Inst. 95 (2003) 1646-1647
8. Sosne G., Siddiqi A., and Kurpakus-Wheater M. Thymosin-beta4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro. Invest. Ophthalmol. Vis. Sci. 45 (2004) 1095-1100
9. Oh S.Y., Song J.H., Gil J.E., Kim J.H., Yeom Y.L., and Moon E.Y. ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance. Exp. Cell Res. 312 (2006) 1651-1657
10. Hsiao H.L., Wang W.S., Chen P.M., and Su Y. Overexpression of thymosin beta-4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively. Carcinogenesis 27 (2006) 936-944
11. Iguchi K., Usami Y., Hirano K., Hamatake M., Shibata M., and Ishida R. Decreased thymosin beta4 in apoptosis induced by a variety of antitumor drugs. Biochem. Pharmacol. 57 (1999) 1105-1111
12. Ji P., Diederichs S., Wang W., Boing S., Metzger R., Schneider P.M., Tidow N., Brandt B., Buerger H., Bulk E., Thomas M., Berdel W.E., Serve H., and Muller-Tidow C. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22 (2003) 8031-8041
13. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990) 4-6
14. Brown J.M. The hypoxic cell: a target for selective cancer therapy - eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 59 (1999) 5863-5870
15. Cho W.K., Seong Y.R., Lee Y.H., Kim M.J., Hwang K.S., Yoo J., Choi S., Jung C.R., and Im D.S. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor. Mol. Ther. 10 (2004) 938-949
16. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93 (2001) 266-276
17. Chan D.A., Krieg A.J., Turcotte S., and Giaccia A.J. HIF gene expression in cancer therapy. Methods Enzymol. 435 (2007) 323-345
18. Wang G.L., Jiang B.H., Rue E.A., and Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
19. Salceda S., and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272 (1997) 22642-22647
20. Huang L.E., Gu J., Schau M., and Bunn H.F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95 (1998) 7987-7992
21. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., and Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835
22. Semenza G.L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19 (2000) 59-65
23. Denizot F., and Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89 (1986) 271-277
24. Gao N., Shen L., Zhang Z., Leonard S.S., He H., Zhang X.G., Shi X., and Jiang B.H. Arsenite induces HIF-1alpha and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Mol. Cell. Biochem. 255 (2004) 33-45
25. Ido Y., Chang K.C., Lejeune W.S., Bjercke R.J., Reiser K.M., Williamson J.R., and Tilton R.G. Vascular dysfunction induced by AGE is mediated by VEGF via mechanisms involving reactive oxygen species, guanylate cyclase, and protein kinase C. Microcirculation 8 (2001) 251-263
26. Kosmidou I., Xagorari A., Roussos C., and Papapetropoulos A. Reactive oxygen species stimulate VEGF production from C(2)C(12) skeletal myotubes through a PI3K/Akt pathway. Am. J. Physiol. Lung Cell. Mol. Physiol. 280 (2001) L585-L592
27. Zhou Q., Liu L.Z., Fu B., Hu X., Shi X., Fang J., and Jiang B.H. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis 28 (2007) 28-37
28. Minet E., Michel G., Mottet D., Raes M., and Michiels C. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic. Biol. Med. 31 (2001) 847-855
29. Michiels C., Minet E., Michel G., Mottet D., Piret J.P., and Raes M. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life 52 (2001) 49-53
30. Mottet D., Michel G., Renard P., Ninane N., Raes M., and Michiels C. ERK and calcium in activation of HIF-1. Ann. NY Acad. Sci. 973 (2002) 448-453
31. Mottet D., Michel G., Renard P., Ninane N., Raes M., and Michiels C. Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J. Cell Physiol. 194 (2003) 30-44
32. Minet E., Arnould T., Michel G., Roland I., Mottet D., Raes M., Remacle J., and Michiels C. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. 468 (2000) 53-58
33. Han Y.H., Kwon J.H., Yu D.Y., and Moon E.Y. Inhibitory effect of peroxiredoxin II (Prx II) on Ras-ERK-NFkappaB pathway in mouse embryonic fibroblast (MEF) senescence. Free Radic. Res. 40 (2006) 1182-1189
34. Janssen-Heininger Y.M., Poynter M.E., and Baeuerle P.A. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic. Biol. Med. 28 (2000) 1317-1327
35. Toledano M.B., and Leonard W.J. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc. Natl. Acad. Sci. USA 88 (1991) 4328-4332
36. Jung Y.J., Isaacs J.S., Lee S., Trepel J., and Neckers L. Microtubule disruption utilizes an NFkappa B-dependent pathway to stabilize HIF-1alpha protein. J. Biol. Chem. 278 (2003) 7445-7452